Overview

Expanded Access Study Of Palbociclib (PD-0332991) In Combination With Letrozole As Treatment Of Post-Menopausal Women With HR-Positive, Her2-Negative Advanced Breast Cancer For Whom Letrozole Therapy Is Deemed Appropriate

Status:
No longer available
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To provide access to palbociclib to post-menopausal women with HR-positive, HER2-negative advanced breast cancer who are deemed appropriate for letrozole therapy (Canada: first-line patients only).
Details
Lead Sponsor:
Pfizer
Treatments:
Letrozole
Palbociclib